Hepatitis C virus antibodies in high risk juvenile onset systemic lupus erythematosus

Area of Science:

• Pediatric Rheumatology
• Infectious Diseases
• Hepatology

Background:

• Juvenile systemic lupus erythematosus (JSLE) is a chronic autoimmune disease.
• Patients with JSLE often undergo immunosuppressive therapy and invasive procedures, potentially increasing infection risk.
• The prevalence of hepatitis C virus (HCV) in this high-risk population is not well-established.

Purpose of the Study:

• To determine the prevalence of HCV infection among patients with JSLE.
• To compare HCV infection rates between JSLE patients and a matched control group.
• To assess the association between JSLE, its treatments, and HCV infection risk factors.

Main Methods:

• A study was conducted on 40 low-income JSLE patients and 20 healthy controls matched for socioeconomic status.
• Anti-HCV antibody testing was performed using a third-generation microparticle enzyme immunoassay.
• Risk factors for HCV infection, including immunosuppressive treatment, hospitalization, and invasive procedures, were recorded.

Main Results:

• The frequency of anti-HCV antibodies was low and comparable between the JSLE group (2.5%) and the control group (0%).
• JSLE patients exhibited significantly higher rates of risk factors for HCV infection, such as immunosuppressive treatment (90%), hospitalization (50%), and invasive procedures (47.5%), compared to controls.
• Despite these risk factors, no significant difference in HCV antibody prevalence was observed.

Conclusions:

• The low prevalence of anti-HCV antibodies in high-risk JSLE patients suggests that HCV is unlikely to play a significant role in the pathogenesis of JSLE.
• HCV screening may be considered in JSLE patients, but the virus does not appear to be a major contributor to the disease itself.